Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
UK-based Proteome Sciences has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval). 18 May 2016
Novartis late yesterday announced major changes to focus its Pharmaceuticals Division by creating two business units reporting to the chief executive: Novartis Pharmaceuticals and Novartis Oncology. 18 May 2016
Japanese pharma major Takeda Pharmaceutical has appointed James Kehoe as its new chief financial officer (CFO), hailing his ‘passion for transforming large organizations’ as key to the company’s growth ambitions. 16 May 2016
Japanese drug major Astellas has appointed Rodrigo Fernandez executive director, international business, with responsibility for managing business in Latin America outside of Brazil. 29 April 2016
Ireland-based Perrigo has announced that Sharon Kochan will lead the expansion of the company’s branded consumer healthcare (BCH) segment. 28 April 2016
Troubled Valeant Pharmaceuticals has named Joseph Papa as its new chief executive, calling him an appointment with “an ethical approach.” 25 April 2016
Maya Martinez-Davis has been appointed as global head of oncology of the biopharma business of German pharma giant Merck KGaA, it was announced on Thursday. 14 April 2016
Starboard Value, a privately owned hedge fund sponsor, has written a strongly-worded letter to US specialty drugmaker Depomed, in which the investor now owns almost 10% of the shares. 11 April 2016
Japanese drugmaker Sosei Group has announced that Peter Bains will take over as both chief operating officer and chief executive in the next three months. 22 March 2016
Valeant Pharmaceuticals International today announced that it has initiated a search for a new chief executive officer, and appointed William Ackman, chief executive of hedge fund Pershing Square Management, to its board of directors. 21 March 2016
US clinical-stage cancer drug develop Threshold Pharmaceuticals has announced the appointment of Stewart Kroll as chief operating officer. 21 March 2016
The chief executive of UK pharma major GlaxoSmithKline, Sir Andrew Witty, will retire in March next year, the company announced on Thursday. 17 March 2016
Canadian drugmaker Valeant Pharmaceuticals has confirmed that executive vice president, company group chairman, Deb Jorn, has resigned from the company with immediate effect. 4 March 2016
Japanese drug major Astellas Pharma has appointed Yukio Matsui as president of EMEA operations, with responsibility for the company’s commercial operations in Europe, the Middle East and Africa, it has been announced. 4 March 2016
Swedish Orphan Biovitrum has released financial results, showing that total net revenue for the fourth quarter of 2015 has increased 15% (+9% at constant currencies) to 814 million kronor ($96.2 million). 26 February 2016